Idogen Running Out Of Survival Options
Swedish Firm Seeking Reverse Merger Solution
With very little cash left in the bank, Idogen is weighing up its options including a reverse merger or liquidation.
You may also be interested in...
Alligator Makes Advances In Pancreatic Cancer
The Swedish biotech is expecting intense discussions with prospective partners for mitazalimab, a couple of years after Janssen returned the rights to the CD40 agonist.
Partner Or Go It Alone? TG Therapeutics Ponders EU Plans For Briumvi
TG Therapeutics has successfully launched Briumvi on its own in the US, despite fierce competition from established same-class MS drugs Ocrevus and Kesimpta, but is still weighing up the pros and cons of partnering for the European market.
Cosentyx Becomes First Biologic Approved For HS In Nearly A Decade
The Swiss major should have a considerable first-to-market advantage over other IL-17 biologics from the likes of UCB and Acelyrin that are also targeting the hidradenitis suppurativa space.